

Theratechnologies' CFO to Attend Cantor Global Healthcare Conference in New York City

Montreal, Canada – September 28, 2018 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will make a presentation at the 2018 Cantor Global Healthcare Conference on October 2, 2018 in New York City.

The presentation will take place from 8:00 a.m. to 8:30 a.m. in Track 3-Empire Ballroom 2 of the Intercontinental Barclay Hotel.

“The Conference represents a wonderful opportunity to showcase our Company and its potential for growth. Trogarzo™ (ibalizumab-uiyk) injection and *EGRIFTA*® (tesamorelin for injection) are giving our Company an unprecedented momentum that I will be happy to illustrate in more details while also presenting our longer-term strategy,” stated Philippe Dubuc, Senior Vice President and Chief Financial Officer, Theratechnologies Inc.

About Theratechnologies

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management's beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the growth of the Corporation based on Trogarzo™, *EGRIFTA*® and potential other initiatives and products.

Forward-looking statements are based on a number of assumptions including that sales of Trogarzo™ and *EGRIFTA*® will continue to grow.

Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, among others, the risk that unexpected events slow the growth of Trogarzo™ and/or result in a decrease in sales of *EGRIFTA*®.

We refer potential investors to the "Risk Factors" section of our annual information form dated February 6, 2018 for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and

uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

-30-

Media inquiries:

Denis Boucher

Vice President, Communications and Corporate Affairs

Tel.: (514) 336-7800, ext. 236